Jaguar Health Reports Q2 2026 Financials

Jaguar Health reported Q2 2026 results showing revenue of about $1.23 million and a net loss of $12.68 million, with six-month revenue of $21.5 million and a net loss of $3.83 million, while highlighting crofelemer data that reduced parenteral support by up to 48% in microvillus inclusion disease and outlining a NDA package targeted for end of 2026 and an NDA submission in Q2 2027. The company also announced an investor webcast for August 19, 2026 to review the quarter and corporate updates, and reiterated its focus on crofelemer for rare gastrointestinal disorders and related partnerships.